BackArno Therapeutics Overview

Arno Therapeutics Accounts Payable

Latest accounts payable for ARNI: $1.1M.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$1.07M
↓ 9.36% YoYΔ $-109974.00 vs prior year quarter

Peer trimmed avg / median

Loading

Arno Therapeutics Accounts Payable History

Loading

Arno Therapeutics vs. peers: Accounts Payable Comparison

Loading

Arno Therapeutics Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Arno Therapeutics (ARNI) FAQ

Arno Therapeutics posts a accounts payable of $1.1M as of September 2016. That compares with $1.2M in the prior-year period — down 9.4% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Arno Therapeutics's accounts payable was $1.2M. The latest reading is $1.1M — a 9.4% year-over-year decrease (period ending September 2016). Use the history and growth charts on this page for a longer lookback.

Accounts Payable is one piece of Arno Therapeutics's financial statement story. At $1.1M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for ARNI's accounts payable usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Arno Therapeutics's other metric pages and overview cover the third.

Judging Arno Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in accounts payable easier to interpret. Start with $1.1M here, then scan peer and history charts to see if the gap is persistent.